相似文献
1
Immunotherapy: A therapeutic reservoir.
Nat Rev Cancer. 2018 Mar 22;18(4):206. doi: 10.1038/nrc.2018.23.
2
Nanobiologics: a real game changer for targeted immunotherapy.
Cardiovasc Res. 2019 May 1;115(6):e52-e53. doi: 10.1093/cvr/cvz078.
3
Immunotherapy: Tear down this wall.
Nat Rev Cancer. 2018 Apr;18(4):205. doi: 10.1038/nrc.2018.22. Epub 2018 Mar 9.
4
Modern immunotherapy of cancer.
Adv Surg. 1991;24:41-68.
5
Immunotherapy: Direct shot.
Nat Rev Immunol. 2018 Mar;18(3):149. doi: 10.1038/nri.2018.10. Epub 2018 Feb 16.
6
Genomics of Immunotherapy-Associated Hyperprogressors-Response.
Clin Cancer Res. 2017 Oct 15;23(20):6376. doi: 10.1158/1078-0432.CCR-17-1990.
7
Genomics of Immunotherapy-Associated Hyperprogressors-Letter.
Clin Cancer Res. 2017 Oct 15;23(20):6374-6375. doi: 10.1158/1078-0432.CCR-17-1480.
8
[Immunotherapy with immune checkpoint inhibitors and hepatitis].
Rev Med Suisse. 2019 May 15;15(651):1017-1021.
9
Immunotherapy: The power of perseverance.
J Thorac Cardiovasc Surg. 2018 Apr;155(4):1775-1776. doi: 10.1016/j.jtcvs.2017.12.002. Epub 2017 Dec 9.
10
Immunotherapy: HLA genotype: good to be different.
Nat Rev Immunol. 2018 Feb;18(2):78-79. doi: 10.1038/nri.2017.220. Epub 2017 Dec 27.
本文引用的文献
1
In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy.
Sci Transl Med. 2018 Feb 21;10(429). doi: 10.1126/scitranslmed.aan3682.
Zotero 插件